Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) ...

Ultragenyx's strong revenue growth, diverse streams, and late-stage pipeline make it a standout in rare disease and gene ...

One concern is that insertional mutagenesis of the lentiviral DNA payload in in vivo CAR-Ts may cause secondary cancers.

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

Introduction: The DNA of a Biotech BoomThe global plasmid DNA manufacturing market is entering a transformative era, driven ...

Valneva receives Brazilian marketing authorization for single-dose vaccine Ixchiq for prevention of disease caused by chikungunya virus: Saint Herblain, France Wednesday, April 16 ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Zoetis received conditional USDA approval for an avian flu vaccine ... Some vaccines use viral vectors, like adenoviruses, to deliver avian influenza antigens. These may be more amenable to ...

In oncology, antibody-drug conjugate (ADC) research continues to be a “hot” area after recently approved drugs from ... adeno-associated virus (AAV) vectors. The first rare disease gene ...

There's plenty of evidence that systemic administration of AAV vectors can cause damage to ... up as more and more countries where it is approved – 43 and counting – agree to reimburse treatment.

The FDA has approved a prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.